Searched for
LUPIN TARGET PRICE
6 pharma stocks that Bernstein sees up to 40% upside potential. Do you own any?Bernstein initiated coverage on six pharma stocks, expressing a positive outlook on the Indian healthcare sector driven by AI, innovation i...- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Stock Radar: This pharma stock showing signs of bottoming out after 7-month consolidation; time to buy?Lupin Ltd, a pharma stock, has broken out of a 7-month consolidation, signaling a potential bull comeback. Experts suggest short-term trade...
- Overweight Lupin, target price Rs 2,500: Axis SecuritiesAxis Securities gives an overweight call on Lupin with a target price of Rs 2500. The company reported a net profit of Rs 858.86 crore for ...
- Overweight on Lupin, target price Rs 2,600: Axis SecuritiesAxis Securities recommends an overweight call on Lupin with a target price of Rs 2600. Lupin's current price is Rs 2160. New launches in th...
- Stock Radar: Pharma stocks in focus! Lupin gains momentum; takes support above 30-WSMALupin peaked at Rs 2,312 on September 5, 2024, but lost momentum, breaching key moving averages on daily charts. A buy signal from the Supe...
- Buy Lupin, target price Rs 2,400: SharekhanSharekhan recommends a buy on Lupin with a target price of Rs 2400, citing strong financial performance and increased EBITDA margin guidanc...
- Overweight on Lupin, target price Rs 2,500: Axis SecuritiesAxis Securities has overweight call on Lupin with a target price of Rs 2,500. The current market price of Lupin is Rs 2,216.
- Lupin shares fall over 4%. Should you buy, sell or hold? Here's what brokerages sayLupin witnessed a fall of over 4% to Rs 838.1 in intra-day trade on BSE after brokerages such as Jefferies, Kotak, and Bernstein maintained...
- Lupin shares hit 52-week high after launch of HIV drug Darunavir in USLupin's shares reached a 52-week high of INR 830.3 after it announced the launch of its Darunavir Tablets to market a generic equivalent of...
- Two stocks with potential to rise by 3% and 7%The markets had a good day on Monday with the Nifty opening in a positive mood and ending the day with more than one percent rise. Technica...
- Lupin shares surge 5% on receiving USFDA approval for Valbenazine CapsulesLupin is a pharmaceutical company headquartered in Mumbai, India. While, it is the third-largest pharmaceutical company in the US by prescr...
- Analysts bearish on 'expensive' Lupin after Q3 disappoints, stock falls 9%Of the 44 analysts, 18 of them have a 'sell' rating while 15 remain neutral. On aggregate, analysts slashed consensus price targets by 4.35...
- Lupin shares jump over 8% after September quarter resultsManufacturing and other expenses were 30% of sales at Rs 1,226.8 crore compared to Rs 1,191.6 crore in Q1 FY2023. Investment in R&D for the...
- Buy Lupin, target price Rs 1100: Emkay GlobalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 33653.72 Crore) operating in Pharmaceuticals s...
- Buy Lupin, target price Rs 1150: Emkay GlobalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 40422.33 Crore) operating in Pharmaceuticals s...
- Buy Lupin, target price Rs 1130: Motilal OswalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 44047.24 Crore) operating in Pharmaceuticals s...
- Centrum cuts target price for CiplaCipla's revenues during Q2FY19 declined 2% YoY while the margin was down by 220 bps.
Load More
